Articles By Estel Grace Masangkay

61. Abbott To Acquire Russian Company Veropharm 6/26/2014

    Earlier this week, Abbott announced that it has agreed to acquire Russian pharmaceutical manufacturer Veropharm. The global healthcare company said it will acquire Limited Liability Company Garden Hills, the holding company that own a major controlling interest in Veropharm.

62. Isis Receives $1M Milestone From GSK For FAP Drug 6/26/2014

    Isis Pharmaceuticals announced this week that it has earned a $1 million milestone payment from GlaxoSmithKline after advancing its investigational drug ISIS-TTR Rx in a Phase II/III study in patients with familial amyloid polyneuropathy (FAP).

63. Madison Vaccines Expands Phase 2 Trial Of Prostate Cancer Vaccine 6/25/2014

    Clinical stage biopharmaceutical company Madison Vaccines Incorporated (MIV) announced that it has begun additional patient enrollment in the expansion of a Phase II clinical trial of its lead candidate MVI-816 (pTVG-HP).

64. Questcor Acquires Global Rights To Novartis' Synacthen 6/25/2014

    Questcor Pharmaceuticals announced that it has closed the transaction to acquire global rights to Synacthen and Synacthen Depot from Novartis Pharma AG and Novartis AG in specific countries outside the U.S.

65. WuXi's Toxicology Facility Passes FDA GLP Inspection 6/23/2014

    WuXi PharmaTech, a pharmaceutical, biotechnology, and medical device R&D services company operating in China and the U.S., announced that its Suzho-located toxicology facility passed Good Laboratory Practice (GLP) inspection by the U.S. Food and Drug Administration (FDA).

66. Avoca And Synthetic Genomics Sign Supply Agreement 6/23/2014

    Pharmachem Laboratories division Avoca announced that it has signed into a supply agreement with Synthetic Genomics (SGI) for the extraction and marketing of natural astaxanthin from a strain of algae developed by SGI’s Genovia Bio business unit.

67. FDA Grants Orphan Drug Status To COTI's Ovarian Cancer Drug COTI-2 6/19/2014
    The U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to Critical Outcome Technologies Inc.’ (COTI) investigational drug COTI-2 for the treatment of ovarian cancer.
68. Lixte's Lead Drug Improves Chemotherapy In Study 6/19/2014
    Drug discovery company Lixte’s lead compound LB-100 increased the efficacy of two anti-cancer drugs against liver cancers in animal models.
69. Alexion's Soliris Granted Orphan Status By The FDA 6/18/2014

    The U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to Alexion Pharmaceuticals’ Soliris (eculizumab) for the treatment of rare disease Myasthenia Gravis (MG).

70. Takeda Launches Hypertension Tablets In Japan 6/18/2014
    Takeda Pharmaceutical announced that it has launched Zacras combination tablets, a fixed-dose combination (FDC) of azilsartan and amlodipine besylate hydrochloride, and Azilva tablets 10mg (azilsartan) for the treatment of hypertension in Japan.